Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics

BACKGROUND: With the promise of disease modifying treatments, there is a need for more specific diagnosis and prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Plasma biomarkers are likely to be utilised to increase diagnostic accuracy and specificity of AD and cognitive dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Fei, Poljak, Anne, Kochan, Nicole A, Raftery, Mark, Brodaty, Henry, Smythe, George A, Sachdev, Perminder S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898732/
https://www.ncbi.nlm.nih.gov/pubmed/24433274
http://dx.doi.org/10.1186/1477-5956-12-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898732/
https://www.ncbi.nlm.nih.gov/pubmed/24433274
http://dx.doi.org/10.1186/1477-5956-12-5

Ejemplares similares